2-amino-6,6-dioxo-4,5,6,7-tetrahydro-6-thieno[2,3-c]thiopyran-3-carboxylic acid ethyl ester | 474843-59-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 噻吩类
• 英文名称: 2-amino-6,6-dioxo-4,5,6,7-tetrahydro-6-thieno[2,3-c]thiopyran-3-carboxylic acid ethyl ester
• 英文别名: ethyl 2-amino-4,7-dihydro-5H-thieno[2,3-c]thiopyran-3-carboxylate 6,6-dioxide；ethyl 2-amino-6,6-dioxo-5,7-dihydro-4H-thieno[2,3-c]thiopyran-3-carboxylate
• CAS: 474843-59-9
• 化学式: C₁₀H₁₃NO₄S₂
• mdl: MFCD06655492
• 分子量: 275.35
• InChiKey: QXEOGEHYHZTZCA-UHFFFAOYSA-N

物化性质

• 沸点：
  582.4±50.0 °C(Predicted)
• 密度：
  1.456±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  17
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  123
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  2-amino-6,6-dioxo-4,5,6,7-tetrahydro-6-thieno[2,3-c]thiopyran-3-carboxylic acid ethyl ester 在 sodium hydroxide 、 TEA 作用下， 以 四氢呋喃 、 乙醇 、 水 为溶剂， 反应 65.0h， 生成 2-(Oxalyl-amino)-6,6-dioxo-4,5,6,7-tetrahydro-thieno[2,3-c]thiopyran-3-carboxylic acid
  参考文献：
  名称：

  Discovery and SAR of a Novel Selective and Orally Bioavailable Nonpeptide Classical Competitive Inhibitor Class of Protein-Tyrosine Phosphatase 1B

  摘要：

  Reversible phosphorylation and dephosphorylation of key proteins on tyrosine residues are important parts of intracellular signaling triggered by hormones and other agents. Recent knock-out studies in mice have identified PTP1B as a potential target for the treatment of diabetes and obesity. As a consequence, a number of academic and industrial groups are aggressively pursuing the development of selective PTP1B inhibitors. In addition, other protein-tyrosine phosphatases (PTPs) appear to be critically involved in major diseases such as cancer and autoimmunity. Given the diversity of PTPs and their potential as drug targets in different diseases, we have taken a broad approach to develop active site-directed selective inhibitors of specific members of this family of enzymes. Using a high throughput screening, we have previously identified 2-(oxalylamino)benzoic acid 3a as a relatively weak but classical competitive inhibitor of several PTPs.(4) On the basis of our early studies, indicating that 3a might be used as a starting point for the synthesis of selective PTP inhibitors, we now present our efforts in expansion of this concept and provide here a number of new chemical scaffolds for the development of inhibitors of different members of the PTP family. Although the core structure of these inhibitors is charged, good oral bioavailability has been observed in rat for some compounds. Furthermore, we have observed enhancement of 2-deoxy-glucose accumulation in C2C12 cells with prodrug analogues.

  DOI：

  10.1021/jm0209026
• 作为产物：
  描述：

  氰乙酸乙酯 、 四氢噻喃-4-酮 1,1-二氧化物 在 吗啉 、 sulfur 作用下， 以 乙醇 为溶剂， 反应 24.0h， 生成 2-amino-6,6-dioxo-4,5,6,7-tetrahydro-6-thieno[2,3-c]thiopyran-3-carboxylic acid ethyl ester
  参考文献：
  名称：

  新的P2X3受体拮抗剂。第1部分：三环化合物的发现和优化。

  摘要：

  嘌呤能P2X3受体是三聚体配体门控离子通道，其拮抗作用是吸引人的但具有挑战性且尚未得到充分验证的药物开发构想。为了鉴定可穿透中枢神经系统的口服活性，有效的人P2X3受体拮抗剂化合物，筛选了Gedeon Richter的化合物集合。对命中的三环化合物系列进行了快速的两步优化过程，重点是提高效力，改善代谢稳定性和CNS渗透性。尝试产生了化合物65，这是一种用于在体内测试P2X3抑制作用的潜在工具化合物。

  DOI：

  10.1016/j.bmcl.2016.07.009

文献信息

• Extra Binding Region Induced by Non-Zinc Chelating Inhibitors into the S₁′ Subsite of Matrix Metalloproteinase 8 (MMP-8)
  作者：Giorgio Pochetti、Roberta Montanari、Christian Gege、Carine Chevrier、Arthur G. Taveras、Fernando Mazza

  DOI：10.1021/jm801166j

  日期：2009.2.26

  The mode of binding and the activity of the first two non-zinc chelating, potent, and selective inhibitors of human neutrophil collagenase are reported. The crystal structures of the catalytic domain of MMP-8, respectively complexed with each inhibitor, reveals that both ligands are deeply inserted into the primary specificity subsite S(1)', where they induce a similar conformational change of the surrounding loop that is endowed with the main specificity determinants of MMPs. Accord to this rearrangement, both inhibitors remove the floor of the pocket formed by the Y227 side-chain, rendering available an extra binding region never explored before. The present data show that potent and more selective inhibitors can be obtained by developing ligands able to interact with the selectivity regions of the enzyme rather than with the catalytic zinc ion, which is the common feature of all MMP members.
• Heterotricyclic metalloprotease inhibitors
  申请人：Gege Christian

  公开号：US20080207607A1

  公开（公告）日：2008-08-28

  The present invention relates generally to azatriocyclic containing pharmaceutical agents, and in particular, to azatricyclic metalloprotease inhibiting compounds. More particularly, the present invention provides a new class of azatricyclic MMP-3, MMP-8 and/or MMP-13 inhibiting compounds, that exhibit an increased potency and selectivity in relation to currently known MMP-13, MMP-8 and MMP-3 inhibitors.
• Heterotricyclic Metalloprotease Inhibitors
  申请人：Gege Christian

  公开号：US20100087420A1

  公开（公告）日：2010-04-08

  The present invention relates generally to azatriocyclic containing pharmaceutical agents, and in particular, to azatricyclic metalloprotease inhibiting compounds. More particularly, the present invention provides a new class of azatricyclic MMP-3, MMP-8 and/or MMP-13 inhibiting compounds, that exhibit an increased potency and selectivity in relation to currently known MMP-13, MMP-8 and MMP-3 inhibitors.
• US7749996B2
  申请人：——

  公开号：US7749996B2

  公开（公告）日：2010-07-06
• New P2X3 receptor antagonists. Part 1: Discovery and optimization of tricyclic compounds
  作者：Gábor Szántó、Attila Makó、Imre Bata、Bence Farkas、Sándor Kolok、Mónika Vastag、Attila Cselenyák

  DOI：10.1016/j.bmcl.2016.07.009

  日期：2016.8

  human P2X3 receptor antagonist compound that can penetrate the central nervous system, the compound collection of Gedeon Richter was screened. A hit series of tricyclic compounds was subjected to a rapid, two-step optimization process focusing on increasing potency, improving metabolic stability and CNS penetrability. Attempts resulted in compound 65, a potential tool compound for testing P2X3 inhibitory

  嘌呤能P2X3受体是三聚体配体门控离子通道，其拮抗作用是吸引人的但具有挑战性且尚未得到充分验证的药物开发构想。为了鉴定可穿透中枢神经系统的口服活性，有效的人P2X3受体拮抗剂化合物，筛选了Gedeon Richter的化合物集合。对命中的三环化合物系列进行了快速的两步优化过程，重点是提高效力，改善代谢稳定性和CNS渗透性。尝试产生了化合物65，这是一种用于在体内测试P2X3抑制作用的潜在工具化合物。